ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0745

Tocilizumab in Monotherapy vs. Combined in Aortitis Associated with Giant Cell Arteritis. Multicenter Open-label Study of 196 Patients
Abstract Number: 0074

Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Abstract Number: 0237

Tofacitinib: A Retrospective Study on Safety and Adverse Effects
Abstract Number: 1769

Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Abstract Number: 1010

Total Cost Risk Scores and Barrier Categories in Patients with Axial Spondyloarthritis and Associated Factors
Abstract Number: 1260

Toward a Treat-to-target Strategy in Juvenile Dermatomyositis: Seeking for Suitable Targets and Optimal Timing of Their Achievement
Abstract Number: 2128

Trabecular Bone Score Curve from a Qatari Population, Data from Qatar Biobank
Abstract Number: 2185

TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, a Feasibility Study
Abstract Number: 1494

Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Abstract Number: 2571

Trajectories of Physical Function in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Abstract Number: 2536

Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Abstract Number: 0940

Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Abstract Number: 0024

Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses
Abstract Number: 0763

Transcriptional Analysis of Both Normal and Abnormal TABs in Biopsy-proven GCA Reveals a Shared Gene Expression Profile Compared to Clinically Diverse Controls
Abstract Number: 1836

Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].